Research by Alessandro Santin, MD, professor of gynecology, obstetrics & reproductive sciences and leader of the Disease Aligned Research Team of the Gynecologic Oncology Program at Smilow Cancer Hospital and Yale Cancer Center, has had his research selected as one of the top five advances of the year by the American Society of Clinical Oncology (ASCO).
Highlighted in ASCO’s 2019 Report on Progress Against Cancer were Santin’s study results showing survival rates for women with certain uterine cancers increased with the use of chemotherapy and the antibody Herceptin. The findings were published in the July 2018 issue of the Journal of Clinical Oncology and later, the National Comprehensive Cancer Network (NCCN) revised its guidelines, which are the recognized standard for clinical policy in cancer care, for women with advanced and recurrent HER2/neu-positive uterine cancer to chemotherapy plus Herceptin based on Dr. Santin’s research finding.
ASCO’s annual report highlights the most important clinical research advances of the past year and identifies priority areas where ASCO believes research efforts should be focused moving forward.